During the past decade, Summa Health System - Barberton Campus conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 79 clinical trials were completed, i.e. on average, 493.8% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 28 clinical trials were completed. i.e. 233.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Summa Health System - Barberton Campus" #1 sponsor was "National Cancer Institute (NCI)" with 41 trials, followed by "Radiation Therapy Oncology Group" with 28 trials sponsored, "Alliance for Clinical Trials in Oncology" with 14 trials sponsored, "SWOG Cancer Research Network" with 10 trials sponsored and "Eastern Cooperative Oncology Group" with 10 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Summa Health System - Barberton Campus" #1 collaborator was "National Cancer Institute (NCI)" with 71 trials as a collaborator, "NRG Oncology" with 43 trials as a collaborator, "Radiation Therapy Oncology Group" with 9 trials as a collaborator, "Cancer and Leukemia Group B" with 6 trials as a collaborator and "NCIC Clinical Trials Group" with 5 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Summa Health System - Barberton Campus" are "Prostate Cancer" (13 trials), "Breast Cancer" (12 trials), "Lung Cancer" (6 trials), "Brain and Central Nervous System Tumors" (4 trials) and "Head and Neck Cancer" (4 trials). Many other conditions were trialed in "Summa Health System - Barberton Campus" in a lesser frequency.

Most popular intervention types in "Summa Health System - Barberton Campus" are "Drug" (97 trials), "Radiation" (57 trials), "Other" (56 trials), "Biological" (39 trials) and "Procedure" (12 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (28 trials), "Quality-of-Life Assessment" (21 trials), "Paclitaxel" (15 trials), "Bevacizumab" (14 trials) and "Cisplatin" (13 trials). Other intervention names were less common.

The vast majority of trials in "Summa Health System - Barberton Campus" are 76 trials for "All" genders, 23 trials for "Female" genders and 17 trials for "Male" genders.

Currently, there are NaN active trials in "Summa Health System - Barberton Campus". undefined are not yet recruiting, 10 are recruiting, 46 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 50 completed trials in Summa Health System - Barberton Campus, 2 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Summa Health System - Barberton Campus, 2 "Phase 1" clinical trials were conducted, 43 "Phase 2" clinical trials and 76 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".